Founded as a Belgian sprl (private limited company) by an experienced group of seasoned healthcare and biotech executives with extensive experience in research, drug development, and commercialisation, Bioxodes is developing a portfolio of high value products derived from natural sources based on research conducted by Prof. Edmond Godfroid. This research was developed in collaboration with academic groups from Université Catholique de Louvain, Facultés Universitaires Notre Dame de la Paix Namur, and Université de Liège.
The Company’s portfolio includes
- Ir-CPI, the first in a novel class of antithrombotics, for the prevention of thrombosis in a range of applications including cardiopulmonary bypass grafting and percutaneous coronary intervention. Thanks to a novel mechanism of action, Ir-CPI is potentially the world’s first injectable antithrombotic which can be used in all patient groups without causing high levels of bleeding and potentially without needing to be reversed or washed out at the end of critical procedures.
- IxAC, a first-in-class anti-inflammatory small peptide inhibiting specifically the alternative complement pathway, for the prevention of renal ischemia.
- Ir-LBP, a ‘‘scavenger’’ of LTB4, for the management of illnesses associated with an increased LTB4 production, for example in chronic obstructive pulmonary disease.
Bioxodes controls issued and pending patents relating to the company’s product portfolio